Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Erasca ( (ERAS) ) has issued an announcement.
On June 24, 2025, Erasca, Inc. held its annual meeting of stockholders where two key matters were voted on. The election of three Class I Directors for a three-year term was confirmed, and the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (ERAS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.
Spark’s Take on ERAS Stock
According to Spark, TipRanks’ AI Analyst, ERAS is a Underperform.
Erasca faces significant financial challenges with no revenue and ongoing losses, which heavily impact its stock score. The technical analysis suggests a potential bearish trend, while the valuation is weak due to persistent losses. These factors collectively indicate a high-risk investment, typical for early-stage biotech firms.
To see Spark’s full report on ERAS stock, click here.
More about Erasca
Erasca, Inc. operates in the biotechnology industry, focusing on developing therapies for cancer treatment.
Average Trading Volume: 1,610,362
Technical Sentiment Signal: Sell
Current Market Cap: $390.9M
Learn more about ERAS stock on TipRanks’ Stock Analysis page.